HER2+ Breast Cancer | Specialty

Hurvitz Highlights Key Developments Made in Metastatic HER2+ Breast Cancer Paradigm

January 23rd 2021

Sara A. Hurvitz, MD, reflects on key pivotal trials and recent regulatory decisions that have propelled progress in metastatic HER2-positive breast cancer.

Trastuzumab Deruxtecan Approved in Europe for HER2+ Metastatic Breast Cancer

January 20th 2021

January 20, 2021 - The antibody-drug conjugate trastuzumab deruxtecan has been granted conditional approval in the European Union for use as a single agent in the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-based regimens.

Adjuvant Systemic Therapy Decision Factors

January 20th 2021

HR-/HER2+ Early Stage Breast Cancer: Standards of Care

January 20th 2021

Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 2

January 14th 2021

Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1

January 13th 2021

Dr. Hurvitz on the Expanding Metastatic HER2+ Breast Cancer Treatment Arsenal

January 7th 2021

Sara A. Hurvitz, MD, discusses the expanding HER2-positive metastatic breast cancer treatment arsenal.

Updated ExteNET Data Raise Questions Over TKI Utility in HER2+ Breast Cancer With Brain Metastases

January 6th 2021

Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.

Dr. Sequist on the Importance of Broad Molecular Testing in Lung Cancer

January 5th 2021

Lecia V. Sequist, MD, MPH, discusses the importance of implementing broad molecular testing in lung cancer.

FDA Grants Fast Track Status to ADC ARX788 for HER2+ Metastatic Breast Cancer

January 5th 2021

January 5th, 2021 -The FDA has granted a fast track designation to the investigational antibody-drug conjugate ARX788 for use as a monotherapy in the treatment of patients with advanced or metastatic HER2-positive breast cancer who have previously received 1 or more HER2-targeted regimens in the metastatic setting.

Homing in on HER2-Targeted Treatment Strategies in Early and Advanced Breast Cancer

January 5th 2021

Clinical risk continues to guide treatment decisions in early-stage HER2-positive breast cancer. The presence of brain metastases has become a driving force for treatment selection in the metastatic setting.

Fixed-Dose Pertuzumab/Trastuzumab Combo Approved in Europe for HER2+ Breast Cancer

December 23rd 2020

December 23, 2020 - The European Commission has approved the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, to be administered via a subcutaneous injection in the treatment of patients with early and metastatic HER2-positive breast cancer.

Dr. Rao on Emerging Treatments in HER2+ Metastatic Breast Cancer

December 17th 2020

Ruta D. Rao, MD, associate professor in the Department of Medicine, Division of Hematology at Rush Medical College, as well as the director of the Coleman Foundation Comprehensive Breast Cancer Clinic and medical director of Rush University Cancer Center, discusses emerging treatments for patients with HER2-positive metastatic breast cancer.

Dr. Jhaveri on Sequencing Treatments in Metastatic HER2+ Breast Cancer

December 17th 2020

Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses sequencing treatments for patients with metastatic HER2-positive breast cancer.

FDA Approves Margetuximab-cmkb Plus Chemo in Pretreated Metastatic HER2+ Breast Cancer

December 16th 2020

December 16, 2020 - The FDA has approved margetuximab-cmkb plus chemotherapy for use in adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which was for metastatic disease.

Trastuzumab Deruxtecan Approaches EU Approval for HER2+ Metastatic Breast Cancer

December 15th 2020

December 15, 2020 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for fam-trastuzumab deruxtecan-nxki for use as a single agent in adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2–based regimens.

Neratinib Improves PFS in HER2+ Breast Cancer With Brain Metastases

December 14th 2020

December 14, 2020 - The combination of neratinib and capecitabine showed a 34% reduction in the risk of disease progression or death compared with lapatinib and capecitabine in patients with HER2-positive breast cancer who had central nervous system metastases at baseline.

EU Panel Recommends Tucatinib for Locally Advanced or Metastatic HER2+ Breast Cancer

December 11th 2020

December 11, 2020 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to tucatinib in combination with trastuzumab and capecitabine for use in adult patients with HER2-positive, locally advanced or metastatic breast cancer who had received at least 2 previous anti-HER2 therapies.

AI-Based Analysis Enhances Prediction of Best Responders for Trastuzumab Deruxtecan

December 11th 2020

December 11, 2020 - Use of a novel HER2 quantitative continuous score was better able to provide an objective and quantitative assessment of HER2 expression to identify patients who are most likely to respond to fam-trastuzumab deruxtecan-nxki.

Bardia Brings to Light Complex Breast Cancer Cases

December 10th 2020

In our exclusive interview, Aditya Bardia, MD, MPH, sheds light on the considerations that should be made leading up to treatment selection in common clinical scenarios in breast cancer.